Advertisement

Current Treatment Options in Pediatrics

, Volume 5, Issue 2, pp 78–92 | Cite as

Chronic Kidney Disease: Treatment of Comorbidities I (Nutrition, Growth, Neurocognitive Function, and Mineral Bone Disease)

  • Amy J. Kogon
  • Lyndsay A. HarshmanEmail author
Pediatric Nephrology (BP Dixon and E Nehus, Section Editors)
  • 16 Downloads
Part of the following topical collections:
  1. Topical Collection on Pediatric Nephrology

Abstract

Purpose of review

This review discusses the complications of nutrition, growth, neurocognitive function, and mineral and bone disorder in pediatric chronic kidney disease. We discuss the most recent evidence-based methods for evaluation and prevention of these complications in addition to treatment strategies to address the complications and mitigate adverse effects.

Recent findings

Frequent nutritional assessment is important, particularly for infants and young children. Due to anorexia, oral aversion, and dietary restrictions, weight gain may be difficult to achieve. Adequate nutrition is important for growth. Children with CKD tend to be short, which can impact quality of life and social achievements. Once nutrition is optimized, growth hormone is an effective, but underutilized strategy to improving terminal height. Mineral and bone disorder is a difficult but common complication of CKD which may present with and be driven by abnormalities in calcium, phosphorus, and parathyroid hormone levels. Treatment strategies include dietary phosphorus restriction, phosphorus binders, and inactive vitamin D and active vitamin D sterols. Effective treatment may reduce the risk for bone deformities, growth abnormalities, fractures, cardiovascular disease, and mortality. Children with CKD also suffer from cognitive difficulties. Control of anemia, aggressive childhood nutrition, and decreased exposure to heavy metals (via dialysate and dietary binding agents) has provided substantial improvement to the more profound neurocognitive sequelae observed prior to the 1990s. Current prevention of cognitive sequelae may best be directed at improved blood pressure control and augmented school support.

Summary

Pediatric CKD has systemic ramifications and can impact all aspects of normal development, including nutrition, growth, bone and mineral metabolism, and neurocognitive function. Regular evaluation for disease complications and prompt treatment can reduce the untoward effects of CKD thereby improving the quality and duration of life.

Keywords

Chronic kidney disease Nutrition Acidosis Recombinant growth hormone Cognition 

Notes

Funding Source

Dr. Harshman is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (1K23DK110443).

Compliance with Ethics Guidelines

Conflict Of Interest

Amy J. Kogon and Lyndsay A. Harshman declare no conflict of interest.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    National Kidney Fountation. KDOQI clinical practice guideline for nutrition in children with CKD: 2008 update. Am J Kidney Dis. 2009;53(3):S1–123.Google Scholar
  2. 2.
    • Ayestaran FW, Schneider MF, Kaskel FJ, Srivaths PR, Seo-Mayer PW, Moxey-Mims M, et al. Perceived appetite and clinical outcomes in children with chronic kidney disease. Pediatr Nephrol. 2016;31(7):1121–7.  https://doi.org/10.1007/s00467-016-3321-9 This paper utilized data from the Chronic Kidney Disease in Children (CKiD) study and highlights the importance of self-reported appetite in the pediatric CKD population. Lower appetite is directly related to diminishing renal function and poorer clinical outcomes, including more hospitalizations and lower quality of life.
  3. 3.
    Warady BA, Kriley M, Belden B, Hellerstein S, Alan U. Nutritional and behavioral-aspects of nasogastric tube-feeding in infants receiving chronic peritoneal-dialysis. Adv Perit D. 1990;6:265–8.Google Scholar
  4. 4.
    Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest. 2005;115(6:1659–65.  https://doi.org/10.1172/JCI22521.CrossRefGoogle Scholar
  5. 5.
    Rodriguez Ayala E, Pecoits-Filho R, Heimburger O, Lindholm B, Nordfors L, Stenvinkel P. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrol Dial Transplant. 2004;19(2):421–6.CrossRefGoogle Scholar
  6. 6.
    Foreman JW, Abitbol CL, Trachtman H, Garin EH, Feld LG, Strife CF, et al. Nutritional intake in children with renal insufficiency: a report of the growth failure in children with renal diseases study. J Am Coll Nutr. 1996;15(6):579–85.CrossRefGoogle Scholar
  7. 7.
    Rees L, Mak RH. Nutrition and growth in children with chronic kidney disease. Nat Rev Nephrol. 2011;7(11):615–23.  https://doi.org/10.1038/nrneph.2011.137.CrossRefGoogle Scholar
  8. 8.
    Rees L, Jones H. Nutritional management and growth in children with chronic kidney disease. Pediatr Nephrol. 2013;28(4):527–36.  https://doi.org/10.1007/s00467-012-2258-x.CrossRefGoogle Scholar
  9. 9.
    Wingen AM, Fabian-Bach C, Schaefer F, Mehls O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet. 1997;349(9059):1117–23.CrossRefGoogle Scholar
  10. 10.
    Kopple JD, Levey AS, Greene T, Chumlea WC, Gassman JJ, Hollinger DL, et al. Effect of dietary protein restriction on nutritional status in the modification of diet in renal disease study. Kidney Int. 1997;52(3):778–91.CrossRefGoogle Scholar
  11. 11.
    Chaturvedi S, Jones C. Protein restriction for children with chronic renal failure. Cochrane Database Syst Rev. 2007;4:CD006863.  https://doi.org/10.1002/14651858.CD006863.Google Scholar
  12. 12.
    Rees L, Shaw V. Nutrition in children with CRF and on dialysis. Pediatr Nephrol. 2007;22(10):1689–702.  https://doi.org/10.1007/s00467-006-0279-z.CrossRefGoogle Scholar
  13. 13.
    Parekh RS, Flynn JT, Smoyer WE, Milne JL, Kershaw DB, Bunchman TE, et al. Improved growth in young children with severe chronic renal insufficiency who use specified nutritional therapy. J Am Soc Nephrol. 2001;12(11):2418–26.Google Scholar
  14. 14.
    Wassner SJ. The effect of sodium repletion on growth and protein turnover in sodium-depleted rats. Pediatr Nephrol. 1991;5(4):501–4.CrossRefGoogle Scholar
  15. 15.
    Kiepe D, Tonshoff B. Insulin-like growth factors in normal and diseased kidney. Endocrinol Metab Clin N Am. 2012;41(2):351–74vii.  https://doi.org/10.1016/j.ecl.2012.04.015.CrossRefGoogle Scholar
  16. 16.
    Maniar S, Kleinknecht C, Zhou X, Motel V, Yvert JP, Dechaux M. Growth hormone action is blunted by acidosis in experimental uremia or acid load. Clin Nephrol. 1996;46(1):72–6.Google Scholar
  17. 17.
    Rodig NM, McDermott KC, Schneider MF, Hotchkiss HM, Yadin O, Seikaly MG, et al. Growth in children with chronic kidney disease: a report from the chronic kidney disease in children study. Pediatr Nephrol. 2014;29(10):1987–95.  https://doi.org/10.1007/s00467-014-2812-9.CrossRefGoogle Scholar
  18. 18.
    Mitch WE. Influence of metabolic acidosis on nutrition. Am J Kidney Dis. 1997;29(5):R46–R8.  https://doi.org/10.1016/S0272-6386(97)90115-3.CrossRefGoogle Scholar
  19. 19.
    de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20(9):2075–84.  https://doi.org/10.1681/Asn.2008111205.CrossRefGoogle Scholar
  20. 20.
    Kausman JY, Powell HR, Jones CL. Anemia in pediatric renal transplant recipients. Pediatr Nephrol. 2004;19(5):526–30.  https://doi.org/10.1007/s00467-004-1427-y.CrossRefGoogle Scholar
  21. 21.
    Boehm M, Riesenhuber A, Winkelmayer WC, Arbeiter K, Mueller T, Aufricht C. Early erythropoietin therapy is associated with improved growth in children with chronic kidney disease. Pediatr Nephrol. 2007;22(8):1189–93.  https://doi.org/10.1007/s00467-007-0472-8.CrossRefGoogle Scholar
  22. 22.
    Kari JA, Gonzalez C, Ledermann SE, Shaw V, Rees L. Outcome and growth of infants with severe chronic renal failure. Kidney Int. 2000;57(4):1681–7.  https://doi.org/10.1046/j.1523-1755.2000.00013.x.CrossRefGoogle Scholar
  23. 23.
    Nissel R, Brazda I, Feneberg R, Wigger M, Greiner C, Querfeld U, et al. Effect of renal transplantation in childhood on longitudinal growth and adult height. Kidney Int. 2004;66(2):792–800.  https://doi.org/10.1111/j.1523-1755.2004.00805.x.CrossRefGoogle Scholar
  24. 24.
    North American Pediatric Renal Transplant Cooperative Study Annual Report. 2014. https://web.emmes.com/study/ped/annlrept/annualrept2014.pdf. Accessed 25 Jan 2019
  25. 25.
    Nissel R, Lindberg A, Mehls O, Haffner D, Pfizer international growth database international B. Factors predicting the near-final height in growth hormone-treated children and adolescents with chronic kidney disease. J Clin Endocrinol Metab. 2008;93(4):1359–65.  https://doi.org/10.1210/jc.2007-2302.CrossRefGoogle Scholar
  26. 26.
    Fine RN, Ho M, Tejani A, North American Pediatric Renal Trasplant Cooperative S. The contribution of renal transplantation to final adult height: a report of the North American pediatric renal transplant cooperative study (NAPRTCS). Pediatr Nephrol. 2001;16(12):951–6.  https://doi.org/10.1007/s004670100002. CrossRefGoogle Scholar
  27. 27.
    Gerson AC, Wentz A, Abraham AG, Mendley SR, Hooper SR, Butler RW, et al. Health-related quality of life of children with mild to moderate chronic kidney disease. Pediatrics. 2010;125(2):e349–57.  https://doi.org/10.1542/peds.2009-0085.CrossRefGoogle Scholar
  28. 28.
    Broyer M, Le Bihan C, Charbit M, Guest G, Tete MJ, Gagnadoux MF, et al. Long-term social outcome of children after kidney transplantation. Transplantation. 2004;77(7):1033–7.CrossRefGoogle Scholar
  29. 29.
    Al-Uzri A, Matheson M, Gipson DS, Mendley SR, Hooper SR, Yadin O, et al. The impact of short stature on health-related quality of life in children with chronic kidney disease. J Pediatr. 2013;163(3):736–41 e1.  https://doi.org/10.1016/j.jpeds.2013.03.016.CrossRefGoogle Scholar
  30. 30.
    Haffner D, Schaefer F, Nissel R, Wuhl E, Tonshoff B, Mehls O. Effect of growth hormone treatment on the adult height of children with chronic renal failure. German study Group for Growth Hormone Treatment in chronic renal failure. N Engl J Med. 2000;343(13):923–30.  https://doi.org/10.1056/NEJM200009283431304.CrossRefGoogle Scholar
  31. 31.
    Mehls O, Lindberg A, Nissel R, Haffner D, Hokken-Koelega A, Ranke MB. Predicting the response to growth hormone treatment in short children with chronic kidney disease. J Clin Endocrinol Metab. 2010;95(2):686–92.  https://doi.org/10.1210/jc.2009-1114.CrossRefGoogle Scholar
  32. 32.
    Akchurin OM, Kogon AJ, Kumar J, Sethna CB, Hammad HT, Christos PJ, et al. Approach to growth hormone therapy in children with chronic kidney disease varies across North America: the Midwest Pediatric Nephrology Consortium report. BMC Nephrol. 2017;18(1):181.  https://doi.org/10.1186/s12882-017-0599-1.CrossRefGoogle Scholar
  33. 33.
    Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, et al. Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. J Am Soc Nephrol. 2016;27(2):543–50.  https://doi.org/10.1681/ASN.2015020152.CrossRefGoogle Scholar
  34. 34.
    •• Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36.  https://doi.org/10.1016/j.kint.2017.04.006 The KDIGO 2017 Clinical Practice Guideline Update is a selective update to the 2009 KDIGO mineral bone disease guidelines. The guidelines are adult- and pediatric-specific and cover the spectrum of non-dialysis CKD to transplant. Pertinent to this update is the diagnosis of bone abnormalities and treatment of CKD-MBD by phosphate lowering and calcium maintenance.
  35. 35.
    Portale AA, Wolf M, Juppner H, Messinger S, Kumar J, Wesseling-Perry K, et al. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol. 2014;9(2):344–53.  https://doi.org/10.2215/CJN.05840513.CrossRefGoogle Scholar
  36. 36.
    Arnlov J, Carlsson AC, Sundstrom J, Ingelsson E, Larsson A, Lind L, et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int. 2013;83(1):160–6.  https://doi.org/10.1038/ki.2012.327.CrossRefGoogle Scholar
  37. 37.
    Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545–52.  https://doi.org/10.1161/CIRCULATIONAHA.108.844506.CrossRefGoogle Scholar
  38. 38.
    Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584–92.  https://doi.org/10.1056/NEJMoa0706130.CrossRefGoogle Scholar
  39. 39.
    Seeherunvong W, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediatr Nephrol. 2012;27(11):2129–36.  https://doi.org/10.1007/s00467-012-2224-7.CrossRefGoogle Scholar
  40. 40.
    Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446–56.  https://doi.org/10.1056/NEJMoa022536.CrossRefGoogle Scholar
  41. 41.
    Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int. 2013;83(5):959–66.  https://doi.org/10.1038/ki.2012.403.CrossRefGoogle Scholar
  42. 42.
    Kumar J, McDermott K, Abraham AG, Friedman LA, Johnson VL, Kaskel FJ, et al. Prevalence and correlates of 25-hydroxyvitamin D deficiency in the chronic kidney disease in children (CKiD) cohort. Pediatr Nephrol. 2016;31(1):121–9.  https://doi.org/10.1007/s00467-015-3190-7.CrossRefGoogle Scholar
  43. 43.
    Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268–77.  https://doi.org/10.1016/S0140-6736(13)60897-1.CrossRefGoogle Scholar
  44. 44.
    Cozzolino M, Gallieni M, Brancaccio D. The mechanisms of hyperphosphatemia-induced vascular calcification. Int J Artif Organs. 2008;31(12):1002–3.CrossRefGoogle Scholar
  45. 45.
    Hruska KA, Choi ET, Memon I, Davis TK, Mathew S. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol. 2010;25(4):769–78.  https://doi.org/10.1007/s00467-009-1337-0.CrossRefGoogle Scholar
  46. 46.
    Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–17.CrossRefGoogle Scholar
  47. 47.
    Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520–8.  https://doi.org/10.1681/ASN.2004070602.CrossRefGoogle Scholar
  48. 48.
    Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2008;52(3):519–30.  https://doi.org/10.1053/j.ajkd.2008.03.020.CrossRefGoogle Scholar
  49. 49.
    Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.  https://doi.org/10.1038/sj.ki.5000414.CrossRefGoogle Scholar
  50. 50.
    Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, et al. Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol. 2010;5(10):1860–6.  https://doi.org/10.2215/CJN.01330210.CrossRefGoogle Scholar
  51. 51.
    Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012;7(1):146–52.  https://doi.org/10.2215/CJN.05940611.CrossRefGoogle Scholar
  52. 52.
    Duquette PJ, Hooper SR, Wetherington CE, Icard PF, Gipson DS. Brief report: intellectual and academic functioning in pediatric chronic kidney disease. J Pediatr Psychol. 2007;32(8):1011–7.  https://doi.org/10.1093/jpepsy/jsm036.CrossRefGoogle Scholar
  53. 53.
    Hooper SR, Gerson AC, Butler RW, Gipson DS, Mendley SR, Lande MB, et al. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(8):1824–30.  https://doi.org/10.2215/CJN.09751110.CrossRefGoogle Scholar
  54. 54.
    Mendley SR, Matheson MB, Shinnar S, Lande MB, Gerson AC, Butler RW, et al. Duration of chronic kidney disease reduces attention and executive function in pediatric patients. Kidney Int. 2015;87(4):800–6.  https://doi.org/10.1038/ki.2014.323.CrossRefGoogle Scholar
  55. 55.
    Lande MB, Mendley SR, Matheson MB, Shinnar S, Gerson AC, Samuels JA, et al. Association of blood pressure variability and neurocognition in children with chronic kidney disease. Pediatr Nephrol. 2016;31(11):2137–44.  https://doi.org/10.1007/s00467-016-3425-2.CrossRefGoogle Scholar
  56. 56.
    Gipson DS, Hooper SR, Duquette PJ, Wetherington CE, Stellwagen KK, Jenkins TL, et al. Memory and executive functions in pediatric chronic kidney disease. Child Neuropsychol. 2006;12(6):391–405.  https://doi.org/10.1080/09297040600876311.CrossRefGoogle Scholar
  57. 57.
    Ruebner RL, Laney N, Kim JY, Hartung EA, Hooper SR, Radcliffe J, et al. Neurocognitive dysfunction in children, adolescents, and young adults with CKD. Am J Kidney Dis. 2016;67(4):567–75.  https://doi.org/10.1053/j.ajkd.2015.08.025. CrossRefGoogle Scholar
  58. 58.
    Harshman LA, Johnson RJ, Matheson MB, Kogon AJ, Shinnar S, Gerson AC, et al. Academic achievement in children with chronic kidney disease: a report from the CKiD cohort. Pediatr Nephrol. 2018;34:689–96.  https://doi.org/10.1007/s00467-018-4144-7.CrossRefGoogle Scholar
  59. 59.
    Qvist E, Pihko H, Fagerudd P, Valanne L, Lamminranta S, Karikoski J, et al. Neurodevelopmental outcome in high-risk patients after renal transplantation in early childhood. Pediatr Transplant. 2002;6(1):53–62.CrossRefGoogle Scholar
  60. 60.
    Warady BA, Belden B, Kohaut E. Neurodevelopmental outcome of children initiating peritoneal dialysis in early infancy. Pediatr Nephrol. 1999;13(9):759–65.  https://doi.org/10.1007/s004670050694.CrossRefGoogle Scholar
  61. 61.
    • Hooper SR, Gerson AC, Johnson RJ, Mendley SR, Shinnar S, Lande MB, et al. Neurocognitive, social-behavioral, and adaptive functioning in preschool children with mild to moderate kidney disease. J Dev Behav Pediatr. 2016;37(3):231–8.  https://doi.org/10.1097/DBP.0000000000000267 The impact of CKD in early development has been widely documented in advanced CKD/ESRD. This paper utilized data from the Chronic Kidney Disease in Children (CKiD) study to detail neurocognitive outcomes for pediatric patients with more mild to moderate CKD. Findings suggest relatively intact functioning for preschool children. Higher eGFR and lack of anemia were associated with more intact developmental level/IQ.
  62. 62.
    Hooper SR, Duquette PJ, Icard P, Wetherington CE, Harrell W, Gipson DS. Social-behavioural functioning in paediatric chronic kidney disease. Child Care Health Dev. 2009;35(6):832–40.  https://doi.org/10.1111/j.1365-2214.2009.00992.x.CrossRefGoogle Scholar
  63. 63.
    Lande MB, Gerson AC, Hooper SR, Cox C, Matheson M, Mendley SR, et al. Casual blood pressure and neurocognitive function in children with chronic kidney disease: a report of the children with chronic kidney disease cohort study. Clin J Am Soc Nephrol. 2011;6(8):1831–7.  https://doi.org/10.2215/CJN.00810111.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of NephrologyChildren’s Hospital of PhiladelphiaPhiladelphiaUSA
  2. 2.Department of PediatricsPerelman School of Medicine at the University of PennsylvaniaPhiladelphiaUSA
  3. 3.Division of Pediatric NephrologyUniversity of Iowa Stead Family Department of PediatricsIowa CityUSA

Personalised recommendations